drugset / Trial / NCT00835211
Desmopressin Acetate 0.2 mg Tablets, Fasting
RandomizedCrossoverOpen-label
Summary
The objective of this study was to compare the single-dose relative bioavailability of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg desmopressin acetate tablets following a 0.8 mg dose under fasting conditions.
Timeline
- Start
- 2003-07
- Primary completion
- 2003-08
- Completion
- 2003-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desmopressin | Peptide | 0.8 mg | — |
Indications
No indication recorded.